HealthQuill Articles by: HealthQuill
The US drug regulator halted Rocket Pharmaceuticals Inc.’s investigational gene therapy for Danon disease after a patient died due to an infection, according to a company statement.
Drugs Health Pharma

FDA halts Rocket’s Danon disease mid-stage therapy as patient dies

HQ Team May 28, 2025: The US drug regulator halted Rocket Pharmaceuticals Inc.’s investigational gene therapy for Danon disease after a patient died

Read More
Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.
Drugs Health Pharma

Eli Lilly to buy SiteOne to grab test inhibitor to treat chronic pain

HQ Team May 28, 2025: Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor

Read More
The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
Drugs Medical Pharma

GSK Plc’s drug to treat COPD gets clearance from US drug regulator

HQ Team May 24, 2025: The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive

Read More
Stanford University researchers have developed a gene-editing technology, which they hope will lead to treatments for neurological diseases as well as traumatic injury.
Uncategorized

‘Mailman’ gene-editing tool carries molecule to exact ‘zip code’

HQ Team May 24, 2025: Stanford University researchers have developed a gene-editing technology, which they hope will lead to treatments for neurological diseases

Read More
A federal judge has issued a temporary restraining order preventing the US administration from revoking Harvard’s ability to enroll international students and to sponsor global scholars.
Health Medical Research

US court restrains Donald Trump administration on Harvard enrollment

HQ Team May 24, 2025: A federal judge has issued a temporary restraining order preventing the US administration from revoking Harvard’s ability to

Read More
Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.
Drugs Health Pharma

France’s Sanofi SA to acquire US-based Vigil Neuroscience for $470 million 

HQ Team May 22, 2025: Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies

Read More
A group of US professors has developed a method to accurately diagnose and treat traumatic brain injuries, providing more rigorous care and preventing premature discussions about halting life support.
Drugs Health Research

New traumatic brain injury test to help prevent early halt of life support

HQ Team May 21, 2025: A group of US professors has developed a method to accurately diagnose and treat traumatic brain injuries, providing

Read More
Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total of $170 million.
Drugs Health Pharma

Governments, philanthropic partners pledge $170 million to WHO

HQ Team May 21, 2025: Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total

Read More
The Food and Drug Administration has come out with new product-specific guidances for developing generic drugs and generating evidence to support abbreviated new drug application approvals.
Drugs Health Pharma

FDA draws up new product guidance for developing generic drugs

HQ Team May 21, 2025: The Food and Drug Administration has come out with new product-specific guidances for developing generic drugs and generating

Read More
Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe Holding, for $256 million.
Drugs Medical Pharma

Regeneron to buy bankrupt 23andMe Holding assets for $256 million

HQ Team May 20, 2025: Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe

Read More